Mankind Pharma Limited has informed the Exchange regarding Appointment of Ms M. K. Kulshrestha & Associates, Cost Accountants as Other of the company w.e.f. May 19, 2026.
MANKIND · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Mankind Pharma reported FY2025-26 standalone revenue of Rs 10,421 crore, up 9.6% from Rs 9,507 crore in prior year. However, standalone profit after tax dropped significantly to Rs 714 crore from Rs 1,786 crore in FY2025. The board approved reappointment of Whole-Time Director Satish Kumar Sharma for 5 years from September 2026, appointment of M.K. Kulshrestha & Associates as Cost Auditors for FY2026-27, and additional investment of up to Rs 500 crore in wholly-owned subsidiary Mankind Medicare Private Limited. Executive Directors (Chairman, Vice Chairman & MD, CEO) voluntarily forwent their commission for FY2025-26 to strengthen cash position for business expansion. The CIO also resigned effective May 31, 2026. Joint statutory auditors issued unmodified opinion; however, comparative prior year figures were restated for BSV acquisition and auditors drew emphasis on pending income tax proceedings.
Sharp PAT decline despite revenue growth is a concern, though the company maintains healthy margins (29% operating, 20% net) and low leverage (debt-equity 0.34). Executive commission waiver and additional subsidiary investment signal focus on cash preservation and expansion. Restatement of prior year results may affect historical comparisons.